LLC1 Metastatic Tumor Model Service for Lung Cancer

The LLC1 Metastatic Tumor Model Service for Lung Cancer provides a uniquely versatile in vivo platform built on the historic Lewis lung carcinoma: a highly metastatic murine line that grows in fully immunocompetent C57BL/6 hosts, enabling both spontaneous and experimental lung metastasis paradigms within an intact immune microenvironment. Alfa Cytology delivers this program with authenticated LLC1 banks — including luciferase-engineered variants — calibrated syngeneic implantation procedures, scheduled bioluminescence and quantitative metastasis monitoring, and terminal organ-by-organ pathology, giving sponsors a complete metastatic cascade readout from primary growth through pulmonary colonization.

Overview of LLC1 Metastatic Tumor Model for Lung Cancer

The Lewis lung carcinoma stands as one of the oldest continuously used tumor models in existence: in 1951 Dr. Margaret Lewis isolated a carcinoma that had arisen spontaneously in the lung of a C57BL mouse, and for decades thereafter the tumor was maintained by serial subcutaneous or intramuscular passage before a culture-adapted cloned line — LLC1, also known as LL/2 — was established in 1980. Whole-exome sequencing has since revealed a hypermutated genome carrying activating Ras-pathway mutations with biallelic Cdkn2a/Cdkn2b loss and deregulation of the RTK/RAS, p53, cell-cycle, TGF-β and Hippo pathways, and has judged the tumor broadly similar to human lung adenocarcinoma. With a doubling time near twenty-one hours and near-uniform take rates, LLC1 forms rapidly growing, highly vascularized tumors with histology faithful to the original carcinoma, and — uniquely among lung cancer models — it is syngeneic to C57BL/6 mice, so the full metastatic process unfolds inside an intact immune system rather than behind an immunodeficient barrier.

Fig 1. Reporter-immune interaction and spontaneous metastasis monitoring in the LLC1 model: 2D/3D BLI-CT of primary LLC tumors, primary tumor resection at week 4, subsequent BLI detection of spontaneous lung and bone metastases, and CBG/GFP reporter stability assessment. (Basnet, Angisha, et al., 2025)

That immune-competent foundation has made LLC1 the reference setting for studying metastasis as a complete biological program. Two paradigms define its use. In the spontaneous metastasis model, cells implanted subcutaneously generate a primary tumor whose growth is tracked and treated on schedule; the primary mass is then surgically resected at a pre-set volume — classically around 800 cubic millimeters — releasing animals to the metastatic phase, in which pulmonary colonization is monitored until endpoint by bioluminescence, quantitative micrometastasis assays, or necropsy lung-nodule counts. In the experimental metastasis model, luciferase-tagged cells are delivered by lateral tail-vein injection on the order of 10⁵ cells, isolating the colonization half of the cascade and producing quantifiable lung lesions within weeks. Both formats rest on decades of accumulated methodology — over five thousand publications since the mid-1950s — and on the model's defining biological behaviors: angiogenesis-driven primary growth, multi-organ spread to lung, lymph node, liver, heart and pancreas, and an immunogenic character that has made it the default syngeneic arena for checkpoint-blockade and combination immunotherapy evaluation, anti-angiogenesis studies, and first-line metastasis-inhibitor screening alike.

Cell Line Information: LLC1

LLC1 — the culture-adapted clone of the Lewis lung carcinoma — carries a pedigree few laboratory reagents can match: isolated in 1951 from a spontaneous lung tumor in a C57BL mouse by Dr. Margaret Lewis, propagated for nearly three decades by serial transplantation, and adapted to monolayer culture in 1980. Its modern molecular portrait, drawn from whole-exome sequencing, reveals a hypermutated adenocarcinoma-like cancer of male C57BL/6 descent bearing activating Ras-pathway mutations, a deleterious Trp53 lesion, biallelic Cdkn2a/Cdkn2b deletion, and deregulation of five core oncogenic pathways. The line adheres to plastic with a doubling time of approximately twenty-one hours, forms discrete colonies suitable for drug-cytotoxicity assays, and retains the anaplastic, highly tumorigenic, vigorously angiogenic character of its parent tumor — seeding lung metastases in syngeneic hosts with histology faithful to the original carcinoma.

Our Services

Alfa Cytology provides the LLC1 metastatic program as a cascade-complete service: murine STR-authenticated banks with luciferase variants on request, calibrated subcutaneous or tail-vein inoculation in immunocompetent C57BL/6 hosts, primary-tumor management with scheduled resection at pre-set volumes, longitudinal bioluminescence and micrometastasis tracking, and terminal organ-by-organ pathology with quantitative lung-nodule analysis — so every stage of the metastatic cascade is captured, measured, and reported.

Workflow of LLC1 Metastatic Tumor Model Construction

Constructing the LLC1 metastatic model is an exercise in cascade engineering: the chosen paradigm determines where the experiment begins and what it measures. The sequence below follows a typical engagement from paradigm selection through pulmonary endpoint analysis.

1. Study design and paradigm selection: The program opens by fixing the paradigm — spontaneous metastasis with a resected primary, or experimental metastasis via tail-vein delivery — together with group sizes, treatment arms and their scheduling relative to inoculation, endpoint criteria, and the monitoring modality (calipers, bioluminescence, or quantitative PCR).
2. Cell authentication and preparation: LLC1 banks are murine STR-verified and mycoplasma-cleared, with luciferase-engineered variants selected up front when in vivo imaging is required, and inoculum concentrations standardized to the paradigm — classically 5 × 10⁶ cells subcutaneously for the spontaneous format.
3. Syngeneic inoculation in C57BL/6 hosts: Immunocompetent female C57BL/6 mice are randomized and implanted subcutaneously for the spontaneous paradigm, or administered cells by lateral tail-vein injection on the order of 10⁵ cells for the experimental-colonization format.
4. Primary tumor growth and treatment window: Primary masses are measured on a fixed schedule — by caliper or bioluminescence — through the therapeutic window, allowing anti-metastatic agents to be dosed prophylactically or concurrently as the study design dictates.
5. Primary tumor resection: In the spontaneous paradigm, primary tumors are surgically excised at the pre-set volume, classically around 800 cubic millimeters, freeing animals to the metastatic phase while removing the confounding influence of primary-mass burden.
6. Metastatic progression monitoring: Animals are tracked through the metastatic phase on schedule with bioluminescence imaging, body-weight and clinical-status checks, and humane endpoints strictly enforced, with metastatic onset date-stamped for each animal.
7. Endpoint organ analysis and reporting: At termination, lungs and the metastatic target organs are harvested for nodule counting, H&E histology, immunohistochemistry, and quantitative micrometastasis assays where specified — with primary-growth, metastatic-burden and survival data consolidated into the final report.

Fig 2. LLC1 Metastatic Tumor Model construction workflow.

Case Study-LLC1 Metastatic Tumor Model Development

Alfa Cytology has deployed the LLC1 metastatic platform in preclinical programs addressing lung cancer dissemination and immune-oncology combinations. Studies of this scope have covered murine STR-verified bank preparation with luciferase variants where imaging was required, syngeneic inoculation in C57BL/6 hosts under either spontaneous or experimental paradigms, scheduled primary-tumor management and resection, longitudinal metastasis monitoring, and terminal quantitative lung-nodule pathology — producing primary-growth, metastatic-burden and survival datasets used for internal candidate decisions. Further detail can be shared upon request as your program defines its direction.

Why Choose Alfa Cytology?

Most metastasis models ask only half the question, measuring either primary growth or colonization in immunodeficient hosts. The LLC1 program at Alfa Cytology is built to answer the whole one — cascade, immune system and all.

• Murine STR-authenticated LLC1 banks with luciferase-engineered variants available on request.
• Both metastatic paradigms under one program: spontaneous resected-primary and experimental tail-vein colonization.
• Immunocompetent C57BL/6 hosts preserving the immune microenvironment that checkpoint and combination programs depend on.
• Calibrated subcutaneous and tail-vein procedures with documented take rates and inoculum standards.
• Longitudinal monitoring combining bioluminescence, quantitative micrometastasis assays and scheduled clinical surveillance.
• Terminal organ-by-organ pathology with quantitative lung-nodule counts as the definitive metastatic endpoint.
• Strictly preclinical operations — research-stage programs receive our complete attention.

Contact Us

If your program needs a metastatic lung cancer setting with its immune system intact — whether for checkpoint combinations, anti-metastatic agents, or angiogenesis studies — reach out to us to design an LLC1 study matched to your paradigm and endpoints. Contact Alfa Cytology today, and our team will return a tailored proposal with cohort designs and projected timelines.

For research use only. Not intended for any clinical use.